^
    Back
    Association details:
    Biomarker:ALK C1156Y
    Cancer:Non Small Cell Lung Cancer
    Drug:Zykadia (ceritinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Drug Des Devel Ther
    Title:

    Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy

    Excerpt:
    All those patients with tumors harboring common ALK resistance mutations, including E1129V, L1196M, C1156Y, I1171T and F1174V, had partial responses with ceritinib, while a patient with G1202R did not respond...
    DOI:
    10.2147/DDDT.S113500